Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Fortrea Holdings Inc. (FTRE:NASDAQ), powered by AI.
Fortrea Holdings Inc. is currently trading at $15.98. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Fortrea Holdings Inc. on Alpha Lenz.
Fortrea Holdings Inc.'s P/E ratio is -1.5.
“Fortrea Holdings Inc. trades at a P/E of -1.5 (undervalued) with modest ROE of -102.4%.”
Ask for details →Fortrea Holdings Inc. is a key player in the clinical research industry, focusing on providing contract research services globally. The company specializes in organizing and managing clinical trials for pharmaceutical and biotechnology firms, aiding them in navigating the complex regulatory and competitive landscape of drug development and approval. Fortrea leverages its expertise to ensure that trials are conducted efficiently and in compliance with stringent international health standards. Its services are crucial in bringing new pharmaceuticals and therapies to market, impacting a variety of sectors, including oncology, cardiology, and neurology. Fortrea’s comprehensive capabilities in trial execution and data management position it as a vital contributor to the advancement of medical science and healthcare solutions, demonstrating its pivotal role in the pharmaceutical supply chain.
“Fortrea Holdings Inc. trades at a P/E of -1.5 (undervalued) with modest ROE of -102.4%.”
Ask for details →Fortrea Holdings Inc. (ticker: FTRE) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 15,500 employees. Market cap is $1.5B.
The current price is $15.98 with a P/E ratio of -1.48x and P/B of 2.59x.
ROE is -102.41% and operating margin is -1.12%. Annual revenue is $2.7B.